News

News

Nextremity Solutions, Inc. Achieves Record Revenue in First Quarter 2017

Nextremity Solutions, Inc., a Strategic Commercialization Organization (SCO) in the musculoskeletal space, located in “The Orthopedic Capital of the World” Warsaw, IN, has achieved record revenue during Q1 2017, exceeding entire revenue for FY 2016. This is the first time in the company’s inception that it was EBITDA positive.

Nextremity Solutions, Inc. recently announced the launch of its i3TM Strategic Solutions service offering. Through the i3 Strategic Solutions strategy, Nextremity will continue to work with surgeons who are thought leaders in their respective fields to develop and commercialize innovative solutions, at present to the foot and ankle market.  In addition to delivering innovative products, Nextremity Solutions, Inc. is committed to establishing effective packaging and delivery systems, creating effective marketing and educational support materials, and providing products with proven sales and clinical efficacy to their industry partners.

“2016 was a year where a new vision was birthed based upon a simple philosophy of doing more of what we do best; more profitably every day. Our passion is to serve surgeons by co-developing innovation to address unmet clinical needs which will improve patient outcomes. Simply said, we are committed to our surgeon designers, their patients, and the strategic partners who recognize the value of our accomplishments,” commented Rod K. Mayer, President and CEO for Nextremity Solutions Inc.

“We are very bullish on our i3 Strategic Solutions strategy. Our recent financial performance is the result of our team’s hard work and dedication to this new strategy. i3 Strategic Solutions has and will continue to produce Revenue ReadyTM products and solutions that are well positioned for our industry partners, worldwide sales and distribution networks. Our focus on working with the leading surgeons in musculoskeletal care and launching our products and technologies through our micro-commercialization process is starting to produce results,” commented Ryan Schlotterback, Chief Commercial Officer for Nextremity Solutions, Inc.

To learn more about i3 Strategic Solutions, visit www.i3strategicsolutions.com.

If you’re a surgeon inventor or have a product idea that you think would be a good fit for Nextremity Solutions, Inc., they can be contacted at 732-383-7901.

Nextremity Solutions: A Company Dedicated to Foot and Ankle Orthopedic Devices

November 8TH, 2016    By: GENE OSTROVSKY

On a recent regional tour of Northeast Indiana’s medtech industry, we stopped off at Nextremity Solutions, a company headquartered in Warsaw, IN, a town known at The Orthopedic Capital. Founded in 2008 by a couple surgeons from Lennox Hill Hospital in New York City, Nextremity has been dedicated from the beginning to introducing innovative new products for foot and ankle care.

This product focus was motivated by the fact that large ortho firms have been channeling the majority of their resources into hip and knee devices. Simpler, cheaper products that address the needs of a more limited population have been overlooked and left to smaller firms to develop. The two surgeons that founded the firm saw the discrepancy in progress of hip and knees products compared to foot and ankle devices, and realized an opportunity to be the ones to close the gap.

FULL STORY…

Nextremity Solutions, Inc. Announces New Strategic Direction for Company Following Zimmer Biomet Announcement

Warsaw, Indiana, October 31, 2016 — Nextremity Solutions, Inc., a musculoskeletal product development company located in “The Orthopedic Capital of the World” Warsaw, IN, recently finalized an exclusive global distribution agreement with Zimmer Biomet for its first four commercialized products, which address unmet clinical needs in forefoot elective surgery.

“Bringing this agreement to closure validates the strategy that our Executive Management Team put into motion at the beginning of the year with the support of our Board of Directors. This strategic shift in our business strategy enables us to focus our efforts on product development and micro-commercialization of innovative technologies in musculoskeletal healthcare,” stated Rod K. Mayer, President and CEO of Nextremity Solutions, Inc.

i3TM Strategic Solutions is Nextremity Solutions’ new strategy to deliver value for Nextremity shareholders and for their industry partners.  Through the i3 Strategic Solutions strategy, Nextremity will continue to work with surgeons who are thought leaders in their respective fields to develop and commercialize innovative solutions, at present to the foot and ankle market.  In addition to delivering innovative products, Nextremity Solutions, Inc. is committed to establishing effective packaging and delivery systems, creating effective marketing and educational support materials, and providing products with proven sales and clinical efficacy to their industry partners.

“Nextremity Solutions, Inc. has learned a lot over the last 4 years, and we’re taking the best of what we do and doing more of it, more profitably, every day.  We’re passionate about serving surgeons, patients, and our industry partners.  This has led us to the introduction of i3 Strategic Solutions and we couldn’t be more excited about our future,” stated Ryan D. Schlotterback, Executive Director, Product Development for Nextremity Solutions, Inc.

“It’s what we call our “micro-commercialization” model and is what makes our solutions very different – and more effective,” commented Schlotterback.

Schlotterback further stated, “i3 Strategic Solutions embodies our vision for Nextremity Solutions and is the right model for our future.  We are committed to our micro-commercialization strategy and believe that we have the opportunity to deliver solutions to the market in a way that truly leverages our strengths and the strengths of our industry partners, while creating the greatest level of value for everyone involved.  We have a very strong internal pipeline and have several external opportunities that we’ve been presented with over the last 6 months that we plan to support with our new model.”

To learn more about i3 Strategic Solutions, visit www.i3strategicsolutions.com.

If you’re a surgeon inventor or have a product idea that you think would be a good fit for Nextremity Solutions, Inc., they can be contacted at 732-383-7901.

 

 

About Nextremity Solutions, Inc.

Nextremity Solutions, Inc. is a privately held musculoskeletal product development company offering innovative solutions and approaches to unmet clinical needs in the mind of surgeons and for the benefit of patients worldwide.

Zimmer Biomet Expands Foot and Ankle Portfolio Through Exclusive Global Distribution Agreement with Nextremity Solutions, Inc.

(WARSAW, IN) October 20, 2016—Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced an exclusive agreement with Nextremity Solutions, Inc. to globally distribute the company’s foot and ankle deformity correction products. The financial terms of the transaction were not disclosed.

“We’re excited to expand the clinical capabilities of our foot and ankle portfolio with Nextremity Solutions’ deformity correction products,” said Brad Quick, General Manager of Zimmer Biomet Foot and Ankle. “The agreement helps advance our commitment to provide customers with the broadest range of cutting-edge technologies and strengthens our position in the foot and ankle market.”

Nextremity Solutions designs and manufactures the following procedure-ready, sterile implant systems for the correction of foot and ankle pathologies, which will be globally distributed by Zimmer Biomet:

  • Nextra® Hammertoe Correction System, the industry’s only adjustable two-piece hammertoe implant.
  • MSP™ Metatarsal Shortening System, an osteotomy guide and implant in one. The innovative design provides precision and stability for metatarsal shortening procedures.
  • Re+Line® Bunion Correction System, a unique, low profile tension-band compression plate designed for performing precise, repeatable bunion correction surgery.
  • ArcusTM Staple System, an arc-styled staple design that provides greater and more uniform compression than conventional staples1.

“The agreement with Zimmer Biomet allows us to expand the reach and influence of our forefoot portfolio by leveraging the commercial capabilities of a global musculoskeletal healthcare leader,” said Rod K. Mayer, President and Chief Executive Officer of Nextremity Solutions, Inc. “Our partnership with Zimmer Biomet enables us to focus on our current strategy of working with our surgeon partners to deliver innovative solutions that help advance the standard of care in the foot and ankle market with speed, efficiency and excellence.”

About Zimmer Biomet

Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

1. Comparison of Compressive Force for Bone Staples, Lisa A. Ferra, Ph.D., OrthoKinetic Technologies LLC and OrthoKinetic Testing Technologies, Southport, NC. Laboratory studies are not necessarily indicative of clinical results.

 

New Study in The Journal of Foot and Ankle Surgery Shows Significant Advantages of Nextremity Solutions, Inc. Hammertoe Device Over Kirschner Wires

Warsaw, Indiana, May 16, 2016 — An article now in press in The Journal of Foot and Ankle Surgery entitled, “Dual-Component Intramedullary Implant Versus Kirschner Wire for Proximal Interphalangeal Joint Fusion: A Randomized Controlled Clinical Trial,” shows significant advantages of using the Nextra® Hammertoe Correction System as opposed to using traditional Kirschner Wires (K-wires) for the treatment of hammertoe deformity.

The Nextra® device is a two-piece implant developed by Nextremity Solutions, Inc., a pure-play foot and ankle orthopedic company located in Warsaw, IN. This device differed from K-wires by achieving more than a 5x higher rate of bone fusion. Additionally, the Nextra® implant exhibited an 84% fusion rate, compared to just 16% with K-wires.

“Some of the issues with the utilization of K-wires in hammertoe surgery are a lack of fusion, lack of rotational stability, risk of infection with post-operative K-Wire exposure, and poor patient satisfaction. According to the study, patients with the Nextra implant not only had drastic improvements in fusion rates but also experienced greater pain relief, a decrease in disability and an increase in activity levels. Simply put, the Nextra patients had greater patient satisfaction outcomes. These clinically proven results help to redefine the standard of care for hammertoe patients,” said Mike Coon, Executive Director of Sales & Marketing for Nextremity Solutions, Inc.

Executive Director of Product Development for Nextremity Solutions, Ryan Schlotterback, commented, “This study is a great example of our commitment to proving the clinical efficacy and benefits of our products and technology. Nextremity Solutions will continue to work with our surgeon partners to develop innovative solutions with improved and proven clinical outcomes. We are steadfast in our belief that the foot and ankle market is primed for continued advancements that lead to better surgical outcomes and patient satisfaction.”

The surgeons involved in this randomized controlled clinical trial are Richard M. Jay, DPM, FACFAS, D. Scot Malay, DPM, MSCE, FACFAS, Adam S. Landsman, DPM, PhD, FACFAS, Nathan Jennato, DPM, James Huish, DPM, and Melissa Younger, DPM. The study is available to subscribers of the journal now at the following link and will be available soon in the printed journal: http://www.jfas.org/article/S1067-2516%2816%2900152-6/abstract.

 

About Nextremity Solutions, Inc.

Nextremity Solutions, Inc. is a privately held medical device company offering innovative solutions and approaches to foot and ankle surgical intervention. The Company’s procedure-ready, sterile implant systems for the correction of foot and ankle pathologies include uniquely precise, proprietary technology designed to achieve repeatable and superior clinical outcomes.

For further information, visit www.nextremitysolutions.com or call Dave Temple, Director of Marketing & Corporate Communications at 574-635-3022.

Nextremity Solutions, Inc. Awarded “2016 Entrepreneurial Firm of the Year”

(Pictured L to R - Rod K. Mayer and Nick A. Deeter)

(Pictured L to R – Rod K. Mayer and Nick A. Deeter)

Warsaw, Indiana, February 2, 2016 — Nextremity Solutions, Inc., a pure-play foot and ankle implant company located in “The Orthopedic Capital of the World” Warsaw, IN, has been awarded, “2016 Entrepreneurial Firm of the Year” by the Kosciusko Chamber of Commerce. Both CEO and Chairman of the Board, Nick Deeter and President, Rod Mayer received the award.

Nextremity Solutions was initially founded in 2008 as a foot and ankle surgical implant company by two New York City orthopedic surgeons. In 2015 the decision was made by Deeter and Mayer to relocate the business from Red Bank, New Jersey to its current location at 210 North Buffalo St. in Warsaw allowing for planned future growth.

Nextremity Solutions brings advanced technology to one of the fastest growing segments of the foot and ankle market by primarily focusing their efforts on the development of proprietary solutions to treat foot and ankle deformities.

“It’s an honor to be a part of this team of dedicated and talented professionals. We work closely with our founding surgeons to ensure that Nextremity Solutions continues to provide innovative solutions for our surgeon customers,” said Nick A. Deeter, CEO and Chairman of the Board for Nextremity Solutions, Inc.

“The team at Nextremity Solutions, Inc. should really be proud. Entrepreneurship can be challenging at times, especially in this space. But, each member of our team brings a unique set of skills that allow us to be a strong and united family. Nextremity Solutions is committed to serving our surgeon partners with excellence. I look forward to seeing this company continue to build our business together one relationship at a time,” commented Rod K. Mayer, President of Nextremity Solutions, Inc.

Through innovation and product design Nextremity Solutions has gained acceptance in the market by providing precise and repeatable outcomes in orthopedic foot and ankle surgery, Worldwide.

Nextremity Solutions, Inc. and BESPA Finalize Strategic Alliance

Warsaw, Indiana, January 21, 2016 — Nextremity Solutions, Inc., a pure-play foot and ankle orthopedic implant company located in “The Orthopedic Capital of the World” Warsaw, IN, has finalized a strategic alliance with BESPA. BESPA is a pioneer in partnering industry with medical professionals to provide solutions that improve patient outcomes.

“Nextremity Solutions, Inc. will be a global industry partner with BESPA; commercializing products and surgical techniques in the foot and ankle segment of the orthopedic market place on a worldwide basis,” said Nick A. Deeter, CEO and Chairman of the Board for Nextremity Solutions, Inc.

This strategic alliance provides Nextremity Solutions, Inc. the opportunity for an immediate and a single-resource access to highly-trained surgeon specialists in research, product ideas, intellectual property, product design, and testing of new technologies.

“We are thrilled to finalize this strategic alliance. As a surgeon-driven company, we are truly grateful for the opportunity to work closely with this premier network of fellowship-trained foot and ankle surgeons. Through the relationships with these talented surgeons, we will be able to continue to provide innovative solutions for the foot and ankle, as well as provide educational programs that are facilitated by surgeons for surgeons,” commented Rod K. Mayer, President of Nextremity Solutions, Inc.

Gregory Pomeroy, MD, CEO and Managing Partner of BESPA stated, “We chose this alliance with Nextremity Solutions, Inc. because we feel they are positioned to both develop new products and to bring these products to market successfully – in this ever changing Healthcare environment.”

Nextremity Solutions, Inc. co-founder and Section Chief, Foot and Ankle Orthopedic Surgery for Lenox Hill Hospital (New York, New York), Stuart D. Katchis, MD stated, “As one of the founders of Nextremity Solutions, Inc., our goal was always to develop innovative products that solved challenges surgeons had with existing technologies and techniques. Through this alliance with BESPA, we can continue to tap into a network of like-minded surgeons and continue to develop innovative solutions that will provide a positive impact on both surgeons and patients.”

Nextremity Solutions, Inc. will also have access to third-party product evaluation of new and existing products, educational programs and training with emphasis on “best-in-class” surgical outcomes, as well as products for patients with foot and ankle problems.

 

About BESPA

BESPA is the pioneer in joining industry and healthcare providers together to develop innovative products, bring these products to market faster, at a lower cost than traditional methods, and educate industry professionals on the products and strategies that will improve patient outcomes.

BESPA offers Medical Professionals an opportunity to be part of the world’s most skilled physician’s network, inspiring talent and innovation around the globe, and improving patient care.

BESPA offers Client Companies access to world renowned HCP’s in many fields. BESPA is driven to provide the medical industry with improved ways to deliver new product solutions through R&D, education, product evaluation and/or design. BESPA consultants are vetted to ensure no cross contamination of ideas or confidentiality issues occur.

 

About Nextremity Solutions, Inc.

Nextremity Solutions, Inc. is a privately held medical device company offering innovative solutions and approaches to foot and ankle surgical intervention. The Company’s procedure-ready, sterile implant systems for the correction of foot and ankle pathologies include uniquely precise, proprietary technology designed to achieve repeatable and superior clinical outcomes.

 

For further information, visit www.nextremitysolutions.com or call Dave Temple, Director of Marketing & Corporate Communications at 574-635-3022.

 

Nextremity Solutions, Inc. Receives FDA 510(k) Approval for the Axi+LineTM Proximal Bunion Correction System

Warsaw, Indiana, December 22, 2015 — Nextremity Solutions, Inc., a surgeon-driven, pure-play foot and ankle orthopedic company located in Warsaw, Indiana, announced it has received 510(k) approval by the Food & Drug Administration to market its upcoming Axi+Line™ Proximal Bunion Correction System.

“The Axi+Line™ Proximal Bunion Correction System represents a significant advancement in the treatment of moderate to severe hallux valgus and is complementary to our Re+Line® Bunion Correction System. The Axi+Line™ system leverages the recognized benefits of the Mau osteotomy, while allowing our surgeons to have confidence in their operative technique. As with our other products, the final repair is very stable thanks to the innovative plating system, giving surgeons peace of mind and patients the potential to quickly get back to their daily activities,” said Director of Product Development, Ryan Schlotterback.

Rod K. Mayer, President of Nextremity Solutions said, “We are very excited to receive 510(k) approval from the FDA for this new and innovative treatment option for patients. I’m extremely proud of our team and their efforts to produce yet another state-of-the-art device for the treatment of deformities in the forefoot. We look forward to taking the next steps to release this product into the hands of our surgeon consultants in our upcoming beta launch.”

The Nextremity Solutions Axi+Line™ Proximal Bunion Correction System is indicated for alignment, stabilization and fusion of fractures, osteotomies and arthrodesis of small bones such as the foot. An application for a CE mark is pending.

About Nextremity Solutions, Inc.

Nextremity Solutions, Inc. is a privately held medical device company offering innovative solutions and approaches to foot and ankle surgical intervention. The Company’s procedure-ready, sterile implant systems for the correction of foot and ankle pathologies include uniquely precise, proprietary technology designed to achieve repeatable and superior clinical outcomes.

For further information, visit www.nextremitysolutions.com or call Dave Temple, Director of Marketing & Corporate Communications at 574-635-3022.

Nextremity Solutions, Inc. Signs Exclusive Agreement with Biotech Company Molecular Matrix, Inc.

Warsaw, Indiana, October 30, 2015 — Nextremity Solutions, Inc., a pure-play foot and ankle company located in Warsaw, IN, recently signed an exclusive agreement with California-based biotechnology company, Molecular Matrix, Inc. (MMI) The agreement will give Nextremity Solutions worldwide exclusive rights for use of Molecular Matrix’s GroCell-3D™ technology, as well as any new musculoskeletal technologies developed by Molecular Matrix for use below the knee.

GroCell-3D™ is an innovative technology for growing mammalian cells and tissues on a three dimensional scaffold. The GroCell-3D™ scaffold has been shown to support the growth of bone, cartilage, heart, nerves, liver, and stem cells among others.

GroCell-3D™ is a 3-dimensional cell scaffold that is safe, highly porous (97% porosity), biocompatible, and biodegradable. Cells cultivated using the GroCell-3D™ scaffold have shown exceptional compatibility and growth. The primary focus in the utilization of the scaffolds unique properties (biocompatible, biodegradable, and osteogenic) is to develop a superior and more cost-effective bone-void filler.

Molecular Matrix founder and inventor of the GroCell-3D™ technology, Charles Lee, Ph.D. said, “As an inventor, I am intrigued to see how this technology is able to be used in real-world situations. Through this partnership, we are able to combine Molecular Matrix’s expertise in biotechnology with Nextremity’s expertise and worldwide surgeon relationships in the foot and ankle market to develop innovative treatment options that will help patients.”

“When I first heard about this technology I knew Nextremity Solutions needed to find a way to work with Molecular Matrix. When you really think about all of the ways this technology could be used in the treatment of foot and ankle degenerative diseases and deformities, you realize that this industry is about to change. We are privileged to partner with the amazing and innovative team at Molecular Matrix,” commented Nick Deeter, CEO and Chairman of Nextremity Solutions, Inc.

Deeter went on to say, “We are so excited about what MMI can do in the musculoskeletal area throughout the human body, that Nextremity has invested in MMI and our CFO, Frank Patton, will be joining their Board of Directors.”

Nextremity Solutions is expected to launch this technology as part of its product portfolio in 2016.

 

About Nextremity Solutions, Inc.

Nextremity Solutions, Inc. is a privately held medical device company offering innovative solutions and approaches to foot and ankle surgical intervention. The Company’s procedure-ready, sterile implant systems for the correction of foot and ankle pathologies include uniquely precise, proprietary technology designed to achieve repeatable and superior clinical outcomes.

 

Nextremity Solutions, Inc. Acquires Foot Fusion Technology from Del Palma Orthopedics

Warsaw, Indiana, October 22, 2015 — Nextremity Solutions, Inc., a pure-play foot and ankle company located in Warsaw, IN, has completed the acquisition of a highly innovative foot fusion technology from Del Palma Orthopedics (DPO) that had previously gained the interest of a larger orthopedic company. DPO, located in Columbia City, IN, is an orthopedic company that focuses on the development of global upper and lower extremities medical devices.

The purchase consists of multiple issued and in-prosecution utility and design patents, associated intellectual property, and partially developed foot fusion devices. The foot fusion technology has immediate applications throughout the foot and ankle, expanding Nextremity Solutions’ product offering. Nextremity also believes this technology also has other applications within other orthopedic market segments.

Ryan Schlotterback, Director of Product Development for Nextremity Solutions said, “The acquisition of this technology not only strengthens our IP portfolio, but also further prepares us as we continue to expand our product development efforts beyond the forefoot to the midfoot and hindfoot.  We believe this technology has the potential to play a role in a number of different procedural applications.”

DPO CFO, Brian More commented, “Del Palma along with key influential surgeons had a vision for a unique system to treat certain conditions in the foot, ankle, hand, and wrist; a system that lowers inventory requirements and increases procedural repeatability that provides for better outcomes.  We are excited to find the right partner in Nextremity Solutions to finish the development and commercialization of the system.  It a privilege to work with partners where goals are aligned; to provide better outcomes for patients and surgeons.”

“The acquisition of the Del Palma technology is another step in Nextremity’s journey to being recognized as the leader in innovation within the foot and ankle market.  Given the interest in this technology by others in the foot and ankle marketplace, Nextremity is excited about obtaining this IP and the opportunity to bring this technology to foot and ankle surgeons in order to improve their patient outcomes,” concluded Frank Patton, CFO for Nextremity Solutions, Inc.

Nextremity Solutions anticipates to launch this technology as part of its product portfolio in the next 12-18 months.

 

About Nextremity Solutions, Inc.

Nextremity Solutions, Inc. is a privately held medical device company offering innovative solutions and approaches to foot and ankle surgical intervention. The Company’s procedure-ready, sterile implant systems for the correction of foot and ankle pathologies include uniquely precise, proprietary technology designed to achieve repeatable and superior clinical outcomes.